0000000000687479

AUTHOR

M.j. Safont

showing 2 related works from this author

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional ad…

2021

BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control. METHODS: In this multicentre, open-label, randomised, controlled, phase 3 trial, participants were recruited from 54 centres in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA. Patients were eligible if they were aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, had a biopsy-prove…

0301 basic medicinemedicine.medical_specialtyPopulationlaw.inventionTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]03 medical and health sciencesFolinic acidAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineRandomized controlled triallawTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]medicineClinical endpointeducationeducation.field_of_studyPerformance statusbusiness.industryTotal mesorectal excisionOxaliplatinSurgery030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessChemoradiotherapymedicine.drugThe Lancet Oncology
researchProduct

First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic c…

2012

Abstract Purpose. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC). Patients and Methods. Patients were randomly assigned to receive six cycles of bevacizumab, capecitabine, and oxaliplatin every 3 weeks followed by XELOX plus bevacizumab or bevacizumab alone until progression. The primary endpoint was the progression-free survival (PFS) interval; secondary endpoints were the overall survival (OS) time, objective resp…

OncologyMaleCancer Researchmedicine.medical_specialtyBevacizumabgenetic structuresColorectal cancerAngiogenesis InhibitorsAntibodies Monoclonal HumanizedCapecitabinechemistry.chemical_compoundMaintenance therapyAcademia-Pharma IntersectInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansbusiness.industryInduction chemotherapymedicine.diseaseeye diseaseshumanitiesOxaliplatinBevacizumabOncologychemistryFluorouracilDeoxycytidineFemalesense organsbusinessColorectal Neoplasmsmedicine.drug
researchProduct